Shionogi & Hsiri collaborate of treating mycobacterial diseases

Japan’s Shionogi has entered into a new license agreement and research collaboration with US biopharma Hsiri Therapeutics to discover and develop additional novel therapeutics for non-tuberculous mycobacterial (NTM) diseases and tuberculosis (TB).

This new collaboration will include technology that complements Shionogi’s earlier collaboration arrangement with Hsiri.

The new tech to be licensed from Hsiri has a novel mechanism of action, will be complementary to Shionogi’s current research with Hsiri, and is anticipated to be more effective than current therapies for mycobacterial infections.

Shionogi’s strength in small molecule drug discovery and development in the antibacterial area will support development of Hsiri’s innovative therapeutics in this collaborative program.

The agreement means that Shionogi will have exclusive worldwide rights to develop, manufacture, and commercialise the compounds generated from the collaboration.

Hsiri will receive an upfront license fee, potential development milestones, and royalty payments based on sales from Shionogi.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news